Emerging drugs for bronchiectasis: An update

Expert Opinion on Emerging Drugs

Volumn 20, Issue 2, 2015, Pages 277-297

  Chang, Anne B ^a,b,c   Marsh, Robyn L ^c   Smith Vaughan, Heidi C ^c   Hoffman, Lucas R ^d  

^a Queensland Children's Medical Research Institute   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adults; Bronchiectasis; Children; Cough; Treatment

Indexed keywords

ACETYLCYSTEINE; AMBROXOL; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; C REACTIVE PROTEIN; CARBOCISTEINE; CIPROFLOXACIN; CORTICOSTEROID; ERDOSTEINE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; N [2 (2,3 DIFLUOROBENZYLTHIO) 6 (2,3 DIHYDROXY 1 METHYLPROPOXY) 4 PYRIMIDINYL] 1 AZETIDINESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PNEUMOCOCCUS VACCINE; ROFLUMILAST; THEOPHYLLINE; TOBACCO SMOKE;

ADULT; ANTIBIOTIC THERAPY; ANTIOXIDANT ACTIVITY; BACTERIAL LOAD; BREATHING EXERCISE; BRONCHIECTASIS; CHILD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE RESPONSE; DELAYED DIAGNOSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; EARLY DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH PROMOTION; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFLUENZA VACCINATION; LUNG ALVEOLUS MACROPHAGE; LUNG CLEARANCE; LUNG FUNCTION; MALE; MORAXELLA CATARRHALIS; MORBIDITY; MUCOCILIARY CLEARANCE; MUCOCILIARY TRANSPORT; MULTICENTER STUDY (TOPIC); NONTYPEABLE HAEMOPHILUS INFLUENZAE; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREVALENCE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FUNCTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING CESSATION; SPUTUM CYTODIAGNOSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; ANIMAL; DRUG DESIGN; RARE DISEASES;

ADULT; ANIMALS; BRONCHIECTASIS; CHILD; DRUG DESIGN; HUMANS; RARE DISEASES;

EID: 84930018062     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2015.1021683     Document Type: Review

References (218)

1. Chang AB, Marsh RL, Smith-Vaughan HC, Hoffman LR. Emerging drugs for bronchiectasis. Expert Opin Emerg Drugs 2012;17(3):361-78
2. King PT, Holdsworth SR, Freezer NJ, et al. Outcome in adult bronchiectasis. COPD 2005;2(1):27-34
3. Chang AB, Masel JP, Boyce NC, et al. Non-CF bronchiectasis-clinical and HRCT evaluation. Pediatr Pulmonol 2003;35(6):477-83
4. Kapur N, Masters IB, Morris PS, et al. Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2012;47(1):68-75
5. King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006;100(4):2183-9
6. Pasteur MC, HelliweSM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162(4):1277-84
7. Seitz AE, Olivier KN, Steiner CA, et al. Trends and burDen of bronchiectasisassociated hospitalizations: USA, 1993-2006. Chest 2010;138(4):944-9
8. Ringshausen FC, De Roux A, Pletz MW, et al. Bronchiectasis-Associated hospitalizations in Germany, 2005-2011: A popuLation-based study of disease burDen and trends. PLoS ONE 2013;8(8):e71109
9. Chang AB, Grimwood K, Macguire G, et al. Management of bronchiectasis and chronic suppurative lung disease (CSLD) in Indigenous children and adults from rural and remote Australian communities. Med J Aust 2008;189(7):386-93
10. Silverman PM, Godwin JD. CT/bronchographic correLations in bronchiectasis. J Comput Assist Tomogr 1987;11(1):52-6
11. HiLE, Ritchie G, Wightman AJ, et al. Comparison between conventional interrupted high-resolution CT and volume multiDetector CT acquisition in the assessment of bronchiectasis. Br J Radiol 2010;83:67-70
12. Chang AB, Redding GJ, Everard ML. State of the Art-Chronic wet cough: protracted bronchitis, chronic suppurative lung disease and bronchiectasis. Pediatr Pulmonol 2008;43(6):519-31
13. Kapur N, Masel JP, Watson D, et al. Bronchoarterial ratio on High Resolution CT scan of the chest in children without pulmonary pathology-Need to reDefine bronchial diLatation. Chest 2011;139(6):1445-50
14. Santamaria F, MontelLa S, Pifferi M, et al. A Descriptive study of non-cystic fibrosis bronchiectasis in a pediatric popuLation from central and southern Italy. Respiration 2009;77(2):160-5
15. Weycker D, EDelsberg J, Oster G, Tino G. Prevalence and economic burDen of bronchiectasis. Clin Pulm Med 2005;12(4):205-9
16. Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in EngLand and Wales. Respir Med 2010;104(7):981-5
17. EinsieDel L, FernanDes L, Spelman T, et al. Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian popuLation. Clin Infect Dis 2012;54(1):43-50
18. OGrady KA, Torzillo PJ, Chang AB. Hospitalisation of Indigenous children in the Northern Territory for lower respiratory illness in the first year of life. Med J Aust 2010;192(10):586-90
19. Twiss J, Metcalfe R, Edwards EA, Byrnes C. New ZeaLand national inciDence of bronchiectasis too high for a Developed country. Arch Dis Child 2005;90(7):737-40
20. Quint JK, Millett E, Hurst JR, et al. Time trends in inciDence and prevalence of bronchiectasis in the UK. Thorax 2012;67:A138
21. Singleton RJ, Morris A, Redding G, et al. Bronchiectasis in ALaska Native children: causes and clinical courses. Pediatr Pulmonol 2000;29(3):182-7
22. FarrePM the prevalence of cystic fibrosis in the European Union. J Cyst Fibros 2008;7(5):450-3
23. Chang AB. Editorial. Bronchiectasis: so much yet to learn and to do. Paediatr Respir Rev 2011;12:89-90
24. AvaiLable from: www.cff.org/AboutCF/[Accessed 24 December 2014]
25. AvaiLable from: www.aihw.gov.au/bronchiectasis [Accessed 4 December 2014]
26. Joish VN, Spilsbury-Cantalupo M, OperschaE, et al. Economic burDen of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health pLan perspective. Appl Health Econ Health Policy 2013;11(3):299-304
27. Schraufnagel DE. editor. Breathing in America: Diseases, Progress, and Hope. American Thoracic Society; 2010
28. Chang AB, Robertson CF, Van Asperen PP, et al. Can a management pathway for chronic cough in children improve clinical outcomes: protocol for a multicentre evaluation. Trials 2010;11(1):103
29. Chang AB, Robertson CF, Van Asperen PP, et al. A multi-centre study on chronic cough in children: burDen and etiologies based on a stanDardized management pathway. Chest 2012;142:943-50
30. Kwak HJ, Moon JY, Choi YW, et al. High prevalence of bronchiectasis in adults: Analysis of CT findings in a health screening program. Tohoku J Exp Med 2010;222(4):237-42
31. Donnelly DE, Critchlow A, Everard ML. Outcomes in children treated for persistent bacterial bronchitis. Thorax 2007;62(1):80-4
32. Gupta S, Siddiqui S, HalDar P, et al. Qualitative analysis of high resolution computed tomography scans in severe asthma. Chest 2009;136(6):1521-8
33. OBrien C, Guest PJ, HiSL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55(8):635-42
34. Martinez-Garcia MA, Soler-Cataluna JJ, Donat SY, et al. Factors associated with bronchiectasis in patients with COPD. Chest 2011;140(5):1130-7
35. Martinez-Garcia MA, De La Rosa CD, Soler-Cataluna JJ, et al. Prognostic value of bronchiectasis in patients with moDerate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187(8):823-31
36. Kim V, Han MK, Vance GB, et al the chronic bronchitic phenotype of COPD: An analysis of the COPDGene Study. Chest 2011;140(3):626-33
37. Montes De OM, Halbert RJ, Lopez MV, et al. Chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J 2012;40(1):28-36
38. Donaldson GC, Wedzicha JA. COPD exacerbations. 1: epiDemiology. Thorax 2006;61(2):164-8
39. Guerra S, SherriDL, Venker C, et al. Chronic bronchitis before age 50 years predicts inciDent airflow limitation and mortality risk. Thorax 2009;64(10):894-900
40. Irwin RS. Complications of cough: Accp eviDence-based clinical practice guiDelines. Chest 2006;129(1 Suppl):54S-58
41. Martinez-Garcia MA, Perpina-TorDera M, Roman-Sanchez P, Soler-Cataluna JJ. Quality-of-life Determinants in patients with clinically stable bronchiectasis. Chest 2005;128(2):739-45
42. Nicotra MB, Rivera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995;108(4):955-61
43. Saynajakangas O, Keistinen T, Tuuponen T, KiveLa SL the course of childhood bronchiectasis: A case report and consiDerations of hospital use. Int J CircumpoLar Health 1998;57(4):276-9
44. Kapur N, Masters IB, Chang AB. Exacerbations in non cystic fibrosis bronchiectasis: clinical features and investigations. Respir Med 2009;103(11):1681-7
45. Cochrane GM. Chronic bronchial sepsis and progressive lung Damage. BMJ 1985;290(6474):1026-7
46. Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease? Heart Lung 2006;35(1):58-65
47. Cole PJ. InfLammation: A two edged sword the moDel of bronchiectasis. Eur J Respir Dis Suppl 1986;147(1):6-15
48. Simons L, Simons J, FriedLanDer Y, McCallum J. Chronic bronchitis and risk of coronary heart disease. Lancet 1996;348(9038):1388-9
49. Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a Large popuLation study. CircuLation 2001;103(8):1064-70
50. HiSL, Burnett D, Hewetson KA, Stockley RA the response of patients with purulent bronchiectasis to antibiotics for four months. Q J Med 1988;66(250):163-73
51. ErDem E, Ersu R, KaraDag B, et al. Effect of night symptoms and disease severity on subjective sleep quality in children with non-cystic-fibrosis bronchiectasis. Pediatr Pulmonol 2011;46(9):919-26
52. Prys-Picard CO, Niven R. Urinary incontinence in patients with bronchiectasis. Eur Respir J 2006;27(4):866-7
53. OLeary CJ, Wilson CB, Hanse DM, et al. ReLationship between psychological well-being and lung health status in patients with bronchiectasis. Respir Med 2002;96(9):686-92
54. Loebinger MR, Wells AU, Hanse DM, et al. Mortality in bronchiectasis: A longterm study assessing the factors influencing survival. Eur Respir J 2009;34:843-9
55. Steinfort DP, Brady S, Weisinger HS, EinsieDel L. Bronchiectasis in Central Australia: A young face to an old disease. Respir Med 2008;102(4):574-8
56. Keistinen T, Saynajakangas O, Tuuponen T, KiveLa SL. Bronchiectasis: An orphan disease with a poorlyunDerstood prognosis. Eur Respir J 1997;10(12):2784-7
57. ManDal P, Sidhu MK, Donaldson LS, et al. Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis. QJM 2013;106(1):27-33
58. Kapur N, Masters IB, Newcombe P, Chang AB the burDen of disease in pediatric non-cystic fibrosis bronchiectasis. Chest 2012;141(4):1018-24
59. Kapur N, Masters IB, Chang AB. Longitudinal growth and lung function in pediatric non-CF bronchiectasis-what influences lung function stability? Chest 2010;138(1):158-64
60. Chalmers JD, Goeminne P, Aliberti S, et al the bronchiectasis severity inDex. An international Derivation and valiDation study. Am J Respir Crit Care Med 2014;189(5):576-85
61. Gao Y, Guan W, Xu G, et al the role of viral infection in pulmonary exacerbations of bronchiectasis in adults: A prospective study. Chest 2014. [Epub ahead of print]
62. Kapur N, Mackay IM, Sloots TP, et al. Respiratory viruses in exacerbations of non-cystic fibrosis bronchiectasis in children. Arch Dis Child 2014;99(8):749-53
63. Redding GJ, Singleton RJ, Valery PC, et al. Respiratory exacerbations in indigenous children from two countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Chest 2014;146(3):762-74
64. Rogers GB, Zain NM, Bruce KD, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc 2014;11(4):496-503
65. Dogru D, Nik-Ain A, Kiper N, et al. Bronchiectasis: the consequence of Late diagnosis in chronic respiratory symptoms. J Trop Pediatr 2005;51(6):362-5
66. Haidopoulou K, CalDer A, Jones A, et al. Bronchiectasis seconDary to primary immunoDeficiency in children: longitudinal changes in structure and function. Pediatr Pulmonol 2009;44(7):669-75
67. Murray MP, TurnbuK, Macquarrie S, Hi AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009;33(2):312-18
68. Bastardo CM, Sonnappa S, Stanojevic S, et al. Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function. Thorax 2009;64(3):246-51
69. Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. Eur Respir J 1997;10(10):2376-9
70. Chang AB, Byrnes CA, Everard ML. Diagnosing and preventing chronic suppurative lung disease (CSLD) and bronchiectasis. Paediatr Respir Rev 2011;12(2):97-103
71. GailLard EA, Carty H, Heaf D, Smyth RL. Reversible bronchial diLatation in children: comparison of serial high-resolution computer tomography scans of the lungs. Eur J Radiol 2003;47(3):215-20
72. Bilton D. UpDate on non-cystic fibrosis bronchiectasis. Curr Opin Pulm Med 2008;14(6):595-9
73. Gharagozlou M, Ebrahimi FA, Farhoudi A, et al. Pulmonary complications in primary hypogammaglobulinemia: A survey by high resolution CT scan. Monaldi Arch Chest Dis 2006;65(2):69-74
74. KaraDag B, Karakoc F, Ersu R, et al. Non-cystic-fibrosis bronchiectasis in children: A persisting problem in Developing countries. Respiration 2005;72(3):233-8
75. Babayigit A, Olmez D, Uzuner N, et al. A neglected problem of Developing countries: noncystic fibrosis bronchiectasis. Ann Thorac Med 2009;4(1):21-4
76. Grimwood K, BeSC, Chang AB. Antimicrobial treatment of non-cystic fibrosis bronchiectasis. Expert Rev Anti Infect Ther 2014;12(10):1277-96
77. Sidhu MK, ManDal P, Hi AT. Developing drug therapies in bronchiectasis. Expert Opin Investig Drugs 2015;24(2):169-81
78. Hare KM, Grimwood K, Leach AJ, et al. Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian Indigenous children with bronchiectasis. J Pediatr 2010;157(6):1001-5
79. Van ElDere J, SLack MP, Ladhani S, Cripps AW. Non-typeable Haemophilus influenzae, an unDer-recognised pathogen. Lancet Infect Dis 2014;14(12):1281-92
80. Chang AB, BeSC, Byrnes CA, et al. Bronchiectasis and chronic suppurative lung disease (CSLD) in children and adults in Australian and New ZeaLand: thoracic Society of Australia and New ZeaLand and Australian Lung FounDation Position Statement. Med J Aust 2010;193(6):356-65
81. Kapur N, Grimwood K, Masters IB, et al. Lower airway microbiology and celluLarity in children with newly diagnosed non-CF bronchiectasis. Pediatr Pulmonol 2012;47(3):300-7
82. Goyal V, Grimwood K, Chang AB. Bronchiectasis: the arrival of better eviDence. Lancet Respir Med 2014;2:12-13
83. HiSL, Morrison HM, Burnett D, Stockley RA. Short term response of patients with bronchiectasis to treatment with amoxycillin given in stanDard or high doses orally or by inhaLation. Thorax 1986;41(7):559-65
84. Lin HC, Cheng HF, Wang CH, et al. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med 1997;155(6):2024-9
85. Wilson CB, Jones PW, OLeary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997;10(8):1754-60
86. Ip M, Shum D, LauDer I, et al. Effect of antibiotics on sputum infLammatory contents in acute exacerbations of bronchiectasis. Respir Med 1993;87(6):449-54
87. Currie DC, Garbett ND, Chan KL, et al. Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q J Med 1990;76(280):799-816
88. Bahous J, Cartier A, Pneau L, et al. Pulmonary function tests and airway responsiveness to methacholine in chronic bronchiectasis of the adult. BuEur Physiopathol Respir 1984;20(4):375-80
89. Ip M, Lam WK, So SY, et al. Analysis of factors associated with bronchial hyperactivity to methacholine in bronchiectasis. Lung 1991;169(1):43-51
90. Twiss J, Stewart AW, Byrnes CA. Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis. Thorax 2006;61(5):414-18
91. Kapur N, BeS, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009(1):CD000996
92. Hernando R, Drobnic ME, Cruz MJ, et al. BuDesoniDe efficacy and safety in patients with bronchiectasis not due to cystic fibrosis. Int J Clin Pharm 2012;34(4):644-50
93. Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia reLated mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ 2013;346:f3306
94. Guran T, Ersu R, KaraDag B, et al. Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis. J Clin Pharm Ther 2008;33(6):603-11
95. Franco F, Sheikh A, Greenstone M. Short acting beta-2 agonists for bronchiectasis. Cochrane Database Syst Rev 2003(1):CD003572
96. Sheikh A, NoLan D, Greenstone M. Long-Acting beta-2-Agonists for bronchiectasis. Cochrane Database Syst Rev 2001(4):CD002155
97. Martinez-Garcia MA, Soler-Cataluna JJ, CataLan-Serra P, et al. Clinical efficacy and safety of buDesoniDe-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012;141(2):461-8
98. Goyal V, Chang AB. Combination inhaled corticosteroids and long-Acting beta2-Agonists for children and adults with bronchiectasis. Cochrane Database Syst Rev 2014(6):CD010327
99. Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 2005;99(1):27-31
100. Kellett F, Robert NM. Nebulised 7%hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011;105(12):1831-5
101. Daviskas E, AnDerson SD, Gomes K, et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005;10(1):46-56
102. Nicolson CH, Stirling RG, Borg BM, et al the long term effect of inhaled hypertonic saline 6%in non-cystic fibrosis bronchiectasis. Respir Med 2012;106(5):661-7
103. Crockett AJ, Cranston JM, Latimer KM, Alpers JH. Mucolytics for bronchiectasis. Cochrane Database Syst Rev 2001(1):CD001289
104. Jones AP, Wallis CE, Kearney CE. Recombinant human Deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2003(3):CD001127
105. ODonneAE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113(5):1329-34
106. Crisafulli E, Coletti O, Costi S, et al. Effectiveness of erdosteine in elDerly patients with bronchiectasis and hypersecretion: A 15-Day, prospective, parallel, open-Label, pilot study. Clin Ther 2007;29(9):2001-9
107. Fuschillo S, De FA, Balzano G. Mucosal infLammation in idiopathic bronchiectasis: celluLar and molecuLar mechanisms. Eur Respir J 2008;31(2):396-406
108. Murray MP, PentLand JL, Hi AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34(5):1086-92
109. Patterson JE, Hewitt O, Kent L, et al. AcapelLa versus usual airway clearance during acute exacerbation in bronchiectasis: A randomized crossover trial. Chron Respir Dis 2007;4(2):67-74
110. Llewellyn-Jones CG, Johnson MM, MitcheJL, et al. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Eur Respir J 1995;8(9):1479-87
111. Kapur N, Chang A. Oral non steroid anti-infLammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007(4):CD006427
112. Pizzutto SJ, Upham JW, Yerkovich ST, Chang AB. Inhaled non-steroid antiinfLammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2010(4):CD007525
113. Katsura H, Ogata M, KiDa K. Factors Determining outcome in elDerly patients with severe COPD on long-term domiciliary oxygen therapy. Monaldi Arch Chest Dis 2001;56(3):195-201
114. FailLa ML. Trace elements and host Defense: recent adVances and continuing challenges. J Nutr 2003;133(5 Suppl 1):1443S-7S
115. Grant CC. Pneumonia in children: becoming harDer to ignore. N Z Med J 1999;112(1095):345-7
116. BLack RE therapeutic and preventive effects of zinc on serious childhood infectious diseases in Developing countries. Am J Clin Nutr 1998;68(2 Suppl):476S-9S
117. Dudley L, Hussey G, Huskissen J, Kessow G. Vitamin A status, other risk factors and acute respiratory infection morbidity in children. S Afr Med J 1997;87(1):65-70
118. HovDen AO, Cox RJ, Haaheim LR. Influenza: the virus and prophyLaxis with inactivated influenza vaccine in at risk groups, including COPD patients. Int J Chron Obstruct Pulmon Dis 2007;2(3):229-40
119. Chang CC, Morris PS, Chang AB. Influenza vaccine for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007(3):CD006218
120. Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2009(2):CD006316
121. Li JS, Peat JK, Xuan W, Berry G. Meta-Analysis on the association between environmental tobacco smoke (ETS) exposure and the prevalence of lower respiratory tract infection in early childhood. Pediatr Pulmonol 1999;27(1):5-13
122. Acharya D, Prasanna KS, Nair S, Rao RS. Acute respiratory infections in children: A community based longitudinal study in south India. Indian J Public Health 2003;47(1):7-13
123. CahiK, Ussher MH. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst Rev 2011(3):CD005353
124. CahiK, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011(2):CD006103
125. Jeffry MoDeCenters Network. Economic Impact Study: comparing Undiagnosed and Diagnosed Patients with Primary ImmunoDeficiencies. 2012. AvaiLable from: http://www info4pi org/scientific-publications/pdf/Economic-Impact-110107 pdf [Accessed 25 March 2012]
126. Lavery KA, ONeiB, Parker M, et al. Expert patient self-management program versus usual care in bronchiectasis: A randomized controlled trial. Arch Phys Med Rehabil 2011;92(8):1194-201
127. Newcombe PA, Sheffield JK, Juniper EF, et al. Development of a parent-proxy quality-of-life chronic cough-specific questionnaire: clinical impact vs psychometric evaluations. Chest 2008;133(2):386-95
128. Milne RJ, Hockey H, Rea H. Long-term air humidification therapy is costeffective for patients with moDerate or severe chronic obstructive pulmonary disease or bronchiectasis. Value Health 2014;17(4):320-7
129. Doeschl-Wilson AB, Davidson R, Conington J, et al. Implications of host genetic variation on the risk and prevalence of infectious diseases transmitted through the environment. Genetics 2011;188(3):683-93
130. Chang AB, Yerkovich ST, Gibson PG, et al. Pulmonary innate immunity in children with protracted bacterial bronchitis. J Pediatr 2012;161:621-5
131. Wong SM, Akerley BJ. Genome-scale approaches to iDentify genes essential for Haemophilus influenzae pathogenesis. Front CeInfect Microbiol 2012;2:23
132. Pizzutto SJ, Yerkovich ST, Upham JW, et al. Children with chronic suppurative lung disease have a reduced capacity to synthesize interferon-gamma in vitro in response to non-typeable Haemophilus influenzae. PLoS ONE 2014;9(8):e104236
133. Tunney MM, Einarsson GG, Wei L, et al the lung microbiota and bacterial abunDance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013;187:1118-26
134. Rogers GB, Van Der Gast CJ, Cuthbertson L, et al. Clinical measures of disease in adult non-CF bronchiectasis correLate with airway microbiota composition. Thorax 2013;68:731-7
135. Van Der Gast CJ, Cuthbertson L, Rogers GB, et al. Three clinically distinct chronic pediatric airway infections share a common core microbiota. Ann Am Thorac Soc 2014;11(7):1039-48
136. Chang AB, Marsh RL, Upham JW, CRE extenDed group. Towards making inroads in reducing the disparity of lung health in Australian Indigenous and New ZeaLand Maori children. Front Pediatr 2015;3:9
137. Kapur N, KaraDag B. Differences and simiLarities in non-CF BE between Developing and affluent countries. Paediatr Respir Rev 2011;12(2):91-6
138. King PT, Holdsworth SR, Farmer M, et al. Phenotypes of adult bronchiectasis: onset of productive cough in childhood and adulthood. COPD 2009;6(2):130-6
139. Stockley RA, Bayley D, HiSL, et al. Assessment of airway neutrophils by sputum colour: correLation with airways infLammation. Thorax 2001;56(5):366-72
140. Goeminne PC, Vandooren J, MoeLants EA, et al the Sputum Colour Chart as a predictor of lung infLammation, proteolysis and Damage in non-cystic fibrosis bronchiectasis: A casecontrol analysis. Respirology 2014;19(2):203-10
141. Chang AB, Grimwood K, MulholLand EK, Torzillo PJ. Bronchiectasis in Indigenous children in remote Australian communities. A position statement. Med J Aust 2002;177(4):200-4
142. Pasteur MC, Bilton D, Hi AT. British Thoracic Society guiDeline for non-CF bronchiectasis. Thorax 2010;65(Suppl 1):i1-i58
143. Chang AB, BeSC, Torzillo PJ, et al. Bronchiectasis and chronic suppurative lung disease (CSLD) in children and adults in Australian and New ZeaLand: Thoracic Society of Australia
144. Chang AB, Bilton D. Non-cystic fibrosis bronchiectasis exacerbations. Thorax 2008;63(3):269-76
145. Quittner AL, ODonneAE, SaLathe MA, et al. Quality of life questionnaire-bronchiectasis: final psychometric analyses and Determination of minimal important difference scores. Thorax 2015;70(1):12-20
146. De Camargo AA, Amaral TS, Rached SZ, et al. Incremental shuttle walking test: A reproducible and valid test to evaluate exercise tolerance in adults with noncystic fibrosis bronchiectasis. Arch Phys Med Rehabil 2014;95(5):892-9
147. Murray MP, TurnbuK, Macquarrie S, et al. ValiDation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34(1):125-31
148. Murray MP, PentLand JL, TurnbuK, et al. Sputum colour: A useful clinical tool in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34(2):361-4
149. Wilson R, Dowling RB, Jackson AD the biology of bacterial colonization and invasion of the respiratory mucosa. Eur Respir J 1996;9(7):1523-30
150. SLauson DO, Hahn FF. Criteria for Development of animal moDels of diseases of the respiratory system: the comparative approach in respiratory disease moDel Development. Am J Pathol 1980;101(3 Suppl):S103-22
151. McNeil C, Macgregor AR, AlexanDer WA. Studies of pneumonia in childhood: IV. Bronchiectasis and fibrosis of the lung. Arch Dis Child 1929;4:170-89
152. Finke W. Prospects for prevention of chronic bronchitis and bronchiectasis; rational management of bronchopulmonary infections by penicillin aerosol therapy. J Pediatr 1948;33(1):29-42
153. Field CE. Bronchiectasis in childhood; III. ProphyLaxis, treatment and progress with a follow-up study of 202 cases of established bronchiectasis. Pediatrics 1949;4(3):355-72
154. Croxatto OC, Lanari A. Pathogenesis of bronchiectasis; experimental study and anatomic findings. J Thorac Surg 1954;27(5):514-28
155. Goeminne PC, Scheers H, Decraene A, et al. Risk factors for morbidity and Death in non-cystic fibrosis bronchiectasis: A retrospective crosssectional analysis of CT diagnosed bronchiectatic patients. Respir Res 2012;13(1):21
156. Stockley RA. Role of bacteria in the pathogenesis and progression of acute and chronic lung infection. Thorax 1998;53(1):58-62
157. DeLarue JA, AbeLanet RM. Pathogenesis of bronchiectasis; an experimental study. Dis Chest 1959;35(4):394-408
158. Beasley V, Joshi PV, Singanayagam A, et al. Lung microbiology and exacerbations in COPD. Int J Chron Obstruct Pulmon Dis 2012;7:555-69
159. Chan TB, Arm JP, AnDerson J, Eiser NM. Pulmonary epithelial permeability in bronchiectasis. Br J Dis Chest 1988;82(1):56-63
160. Marsh RL, Thornton RB, Smith-Vaughan HC, et al. IDentification of biofilm in bronchoalveoLar Lavage from children with bronchiectasis without Pseudomonas aeruginosa infection. Pediatr Pulmonol 2014. [Epub ahead of print]
161. Zawrotniak M, RapaLa-Kozik M. Neutrophil extracelluLar traps (NETs)-formation and implications. Acta Biochim Pol 2013;60(3):277-84
162. Kapur N, Grimwood K, Masters IB, et al. BronchoalveoLar Lavage fluid microbiology and airway celluLarity in children newly diagnosed with bronchiectasis. Respirology 2010;15(Suppl 2):A29
163. Simpson JL, GrisseTV, Douwes J, et al. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007;62(3):211-18
164. Pizzutto SJ, Grimwood K, Bauert P, et al. Bronchoscopy contributes to the clinical management of Indigenous children newly doagnosed with noncystic fibrosis bronchiectasis. Pediatr Pulmonol 2013;48(1):67-73
165. Ayars GH, Altman LC, Gleich GJ, et al. Eosinophil-And eosinophil granulemediated pneumocyte injury. J Allergy Clin Immunol 1985;76(4):595-604
166. Cowburn AS, Condliffe AM, Farahi N, et al. AdVances in neutrophil biology: clinical implications. Chest 2008;134(3):606-12
167. Meijer M, Rijkers GT, Van Overveld FJ. Neutrophils and emerging targets for treatment in chronic obstructive pulmonary disease. Expert Rev Clin Immunol 2013;9(11):1055-68
168. Filep JG. Resolution of infLammation: leukocytes and molecuLar pathways as potential therapeutic targets. Front Immunol 2013;4:256
169. Sabroe I, Whyte MK. Toll-like receptor (TLR)-based networks reguLate neutrophilic infLammation in respiratory disease. Biochem Soc Trans 2007;35(Pt 6):1492-5
170. Vandivier RW, Henson PM, DougLas IS. Burying the Dead: the impact of failed apoptotic ceremoval (efferocytosis) on chronic infLammatory lung disease. Chest 2006;129(6):1673-82
171. Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in COPD. Am J Respir Crit Care Med 2008;178(2):139-48
172. Hodge S, Hodge G, Scicchitano R, et al. AlveoLar macrophages from subjects with chronic obstructive pulmonary disease are Deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol CeBiol 2003;81(4):289-96
173. Hodge S, Hodge G, Ahern J, et al. Smoking alters alveoLar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am J Respir CeMol Biol 2007;37(6):748-55
174. Hodge S, Hodge G, Holmes M, Reynolds PN. Increased airway epithelial and T-ceapoptosis in COPD remains Despite smoking cessation. Eur Respir J 2005;25(3):447-54
175. Voglis S, Quinn K, Tullis E, et al. Human neutrophil peptiDes and phagocytic Deficiency in bronchiectatic lungs. Am J Respir Crit Care Med 2009;180(2):159-66
176. Hodge S, Hodge G, Brozyna S, et al. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveoLar macrophages. Eur Respir J 2006;28(3):486-95
177. El KD, Filep JG. Targeting neutrophil apoptosis for enhancing the resolution of infLammation. Cells 2013;2(2):330-48
178. Kistemaker LE, Van Os RP, Dethmers-Ausema A, et al. Muscarinic M3 receptors on structural cells reguLate cigarette smoke-induced neutrophilic airway infLammation in mice. Am J Physiol Lung CeMol Physiol 2015;308(1):96-L103
179. Gilley SK, Stenbit AE, Pasek RC, et al. Deletion of airway cilia results in noninfLammatory bronchiectasis and hyperreactive airways. Am J Physiol Lung CeMol Physiol 2014;306(2):L162-9
180. Cheng KK the experimental production of bronchiectasis in rats. J Pathol Bacteriol 1954;67(1):89-98
181. Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007;52(9):1176-93
182. King PT, Ngui J, GunawarDena D, et al. Systemic humoral immunity to nontypeable Haemophilus influenzae. Clin Exp Immunol 2008;153(3):376-84
183. King PT, Lim S, Pick A, et al. Lung T-ceresponses to nontypeable Haemophilus influenzae in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013;131(5):1314-21
184. Anwar GA, Bourke SC, AfoLabi G, et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008;102(10):1494-6
185. Daviskas E, AnDerson SD, Eberl S, et al. InhaLation of dry powDer mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999;159(6):1843-8
186. Daviskas E, AnDerson SD, Young IH. Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis. Respir Med 2010;104(3):371-7
187. Bilton D, Daviskas E, AnDerson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powDer mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013;144(1):215-25
188. Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: A randomised, controlled trial. Thorax 2014. 69. 12. 1073-9
189. Bilton D, Bellon G, Charlton B, et al. Pooled analysis of two Large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros 2013;12(4):367-76
190. Cataldi M, Sblendorio V, Leo A, Piazza O. Biofilm-DepenDent airway infections: A role for ambroxol? Pulm Pharmacol Ther 2014;28(2):98-108
191. Pinner NA, Hamilton LA, Hughes A. RoflumiLast: A phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. Clin Ther 2012;34(1):56-66
192. Fabbri LM, Beghe B, Yasothan U, Kirkpatrick P. RoflumiLast. Nat Rev Drug Discov 2010;9(10):761-2
193. Nicholls DJ, Tomkinson NP, Wiley KE, et al. IDentification of a putative intracelluLar allosteric antagonist bindingsite in the CXC chemokine receptors 1 and 2. Mol Pharmacol 2008;74(5):1193-202
194. Chapman RW, Phillips JE, Hipkin RW, et al. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009;121(1):55-68
195. Pavord I, De Soyza A, Elborn JS, et al. Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis. Eur Respir J 2013;42(Suppl 57):P1593
196. Ito K, Lim S, Caramori G, et al. A molecuLar mechanism of action of theophylline: induction of histone DeacetyLase activity to Decrease infLammatory gene expression. Proc Natl Acad Sci USA 2002;99(13):8921-6
197. Barker AF, ODonneAE, Flume P, et al. Aztreonam for inhaLation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, pLacebocontrolled phase 3 trials. Lancet Respir Med 2014;2(9):738-49
198. Chiu AG, Chen B, Palmer JN, et al. Safety evaluation of sinus surfactant solution on respiratory cilia function. Int Forum Allergy Rhinol 2011;1(4):280-3
199. Matera MG, Calzetta L, Segreti A, CazzoLa M. Emerging drugs for chronic obstructive pulmonary disease. Expert Opin Emerg Drugs 2012;17(1):61-82
200. Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010;19(5):330-8
201. Ip M, Lam WK, Chan JC, Liong E. Systemic effects of infLammation in bronchiectasis. Respir Med 1991;85(6):521-5
202. ManDal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: A randomised controlled trial. Lancet Respir Med 2014;2(6):455-63
203. Mutak S. AzaliDes from azithromycin to new azaliDe Derivatives. J Antibiot (Tokyo) 2007;60(2):85-122
204. Zarogoulidis P, Papanas N, Kioumis I, et al. MacroliDes: from in vitro antiinfLammatory and immunomoduLatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012;68(5):479-503
205. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 2010;36(3):646-54
206. Starner TD, Shrout JD, Parsek MR, et al. subinhibitory concentrations of azithromycin Decrease nontypeable Haemophilus influenzae biofilm formation and diminish established biofilms. Antimicrob Agents Chemother 2008;52(1):137-45
207. AvaiLable from: www uspto gov/web/patents/patog/week51/OG/html/1373-3/US08080529-20111220 html 2012
208. FoxweAR, Cripps AW, Dear KB. Haemophilus influenzae oral whole cevaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database Syst Rev 2006(4):CD001958
209. Tandon MK, Phillips M, Waterer G, et al. Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest 2010;137(4):805-11
210. Pizzutto SJ, Yerkovich ST, Upham JW, et al. Improving immunity to Haemophilus influenzae in children with chronic suppurative lung disease. Vaccine 2015;33(2):321-6
211. De BF, Sevieri G. Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: A state of the art. Multidiscip Respir Med 2013;8(1):33
212. CazzoLa M, Anapurapu S, Page CP. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: A meta-Analysis. Pulm Pharmacol Ther 2012;25(1):62-8
213. King PT, Hutchinson P, Holmes PW, et al. Assessing immune function in adult bronchiectasis. Clin Exp Immunol 2006;144(3):440-6
214. King P, Bnett-Wood V, Hutchinson P, et al. BactericiDal activity of neutrophils with reduced oxiDative burst from adults with bronchiectasis. APMIS 2009;117(2):133-9
215. Ruchaud-Sparagano MH, Gertig H, Hester KL, et al. Effect of granulocytemacrophage colony-stimuLating factor on neutrophil function in idiopathic bronchiectasis. Respirology 2013;18(8):1230-5
216. Chang AB. Specialty grand challenge-pediatric pulmonology. Front Pediatr 2013;1:14
217. CampbeF, Conti G, Heckman JJ, et al. Early childhood investments substantially boost adult health. Science 2014;343(6178):1478-85
218. Matsuoka S, Uchiyama K, Shima H, et al. Bronchoarterial ratio and bronchial wathickness on high-resolution CT in asymptomatic subjects: correLation with age and smoking. Am J Roentgenol 2003;180(2):513-18